Plain-English translation of NCT05283174 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research examines how a class of blood clot prevention medications called NOACs (non-vitamin K antagonist oral anticoagulants) — which includes dabigatran, rivaroxaban, apixaban, and edoxaban — affect stroke severity and recovery in people with atrial fibrillation. Researchers will measure medication levels in your blood when you arrive at the hospital with a stroke and track your recovery over the following months and years. The goal is to understand whether staying on the medication, switching treatments, or stopping it affects your long-term outcomes.
Doctors currently don't have clear guidelines about whether patients should continue, change, or stop their blood clot prevention medication after a stroke. By measuring medication levels and tracking recovery in real patients, this study aims to provide evidence to help doctors make better decisions about stroke prevention in the months and years after a stroke.
You likely qualify if…
You likely don't qualify if…
When you arrive at the hospital with a stroke, researchers will draw blood to measure your medication level and document your stroke symptoms. Over the next 90 days, they will track your recovery and functional ability. If you're enrolled in the longer-term follow-up, you'll be monitored for up to one year after your stroke, with researchers tracking what medications you're taking for stroke prevention and how you're doing. The study uses hospital records and national health insurance data, so much of the follow-up happens through your medical care rather than requiring extra visits.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
Taiwan